PD-L1 Tumor Proportion Score (TPS)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-PDL1-TPS |
|---|---|
| Type | Biomarker |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | None declared |
Biomarker Facts
| Biomarker type | protein_expression_ihc |
|---|---|
| Measurement | MethodIHC (22C3, SP263, SP142, 28-8 — pembrolizumab uses 22C3) Unitspercent of viable tumor cells with membranous PD-L1 staining Typical range
|
| Related biomarkers | None declared |
Notes
Universal at metastatic NSCLC diagnosis. Distinguishes ICI-monotherapy candidates from combination-therapy population.
Used By
Actionability
BMA-PDL1-TPS-NSCLC- PD-L1 Tumor Proportion Score (TPS) is the primary predictive biomarker for pembrolizumab...
Biomarker
BIO-PDL1-22C3-CLONE- PD-L1 IHC — Dako 22C3 pharmDx cloneBIO-PDL1-28-8-CLONE- PD-L1 IHC — Dako 28-8 pharmDx cloneBIO-PDL1-SP142-CLONE- PD-L1 IHC — Ventana SP142 cloneBIO-PDL1-SP263-CLONE- PD-L1 IHC — Ventana SP263 clone
Indications
IND-NSCLC-2L-DATO-DXD- IND-NSCLC-2L-DATO-DXDIND-NSCLC-ELDERLY-CARBO-PEM-MOD- IND-NSCLC-ELDERLY-CARBO-PEM-MODIND-NSCLC-PDL1-22C3-PEMBRO-CLONE-SPECIFIC- IND-NSCLC-PDL1-22C3-PEMBRO-CLONE-SPECIFICIND-NSCLC-PDL1-HIGH-MET-1L- IND-NSCLC-PDL1-HIGH-MET-1LIND-NSCLC-PDL1-LOW-NONSQ-MET-1L- IND-NSCLC-PDL1-LOW-NONSQ-MET-1L
Questionnaires
QUEST-NSCLC-1L-STUB- Non-small cell lung cancer — first line
Red flag
RF-NSCLC-PDL1-50-PLUS- Metastatic NSCLC with PD-L1 tumor proportion score (TPS) ≥50% by 22C3 IHC, no actionable...
Tests
TEST-PDL1-IHC- PD-L1 IHC (TPS for NSCLC)